Interview with Dr. Hedy Lee Kindler Now Available on Demand

Share Article

The interview with Dr. Hedy Lee Kindler, University of Chicago Medicine, which was broadcast live on Thursday, April 23, by the Mesothelioma Applied Research Foundation, is now available on demand on the Foundation’s website.

Not only do these drugs shrink tumors, but they have sustained and prolonged responses

On Thursday, April 23, the Mesothelioma Applied Research Foundation interviewed Dr. Hedy Lee Kindler, University of Chicago Medicine, during its ‘Meet the Mesothelioma Experts’ series. The interview was the first in the series focusing on mesothelioma centers of excellence. Dr. Kindler was interviewed by the Meso Foundation’s executive director, Mary Hesdorffer, with whom she discussed the pleural and peritoneal mesothelioma programs at the University of Chicago Medicine, as well as the latest clinical trials available, including the promising PD-1 inhibitor trial using pembrolizumab (KeytrudaTM).

In the interview, Dr. Kindler explains that pembrolizumab demonstrated a very high response rate and even higher rate of disease control.

“Not only do these drugs shrink tumors, but they have sustained and prolonged responses,” said Dr. Kindler. “We designed a trial that just opened a few weeks ago that uses pembrolizumab and is the first phase 2 trial in which everyone gets the drug,” she added.

The full interview is now available on demand on the Meso Foundation’s website at

Dr. Kindler is the Director of Mesothelioma and Gastrointestinal Programs at the University of Chicago Medicine. She is an internationally recognized cancer expert who specializes in the medical management of pleural and peritoneal mesothelioma. Her research focuses on the investigation of novel agents for mesothelioma, and she designs and leads many innovative clinical trials for this disease.

You can listen to previous Meet the Mesothelioma Experts sessions on our Meet the Mesothelioma Experts page.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards.

The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $9 million to research. More information is available at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Maja Belamaric
Follow us on
Visit website